scholarly journals Interview: Future directions for PET in colorectal cancer

2012 ◽  
Vol 1 (4) ◽  
pp. 301-307
Author(s):  
Anthony Frank Shields
Keyword(s):  
Colorectal Cancer ◽  
Future Directions

Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer

2020 ◽  
Vol 21 (14) ◽  
pp. 1397-1404
Author(s):  
Adrian Bartoszek ◽  
Jakub Fichna ◽  
Aleksandra Tarasiuk ◽  
Agata Binienda ◽  
Adam Fabisiak ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Fatty Acid ◽  
Free Fatty Acid ◽  
Current Knowledge ◽  
Developed Countries ◽  
Future Directions ◽  
Screening Programs ◽  
Pharmacological Targets ◽  
The Family ◽  
Free Fatty Acid Receptors

Colorectal cancer (CRC) is one of the most common cancers worldwide. In developed countries, its mortality remains high, yet the prevalence has established owing to effective screening programs; however due to the westernization of lifestyle, the incidences in many other countries have increased. Although the treatment of CRC has improved in the last few years, the side effects of these approaches cannot be neglected. Recently, members of the family of free fatty acid receptors (FFARs) have become attractive pharmacological targets in many diseases, including asthma; studies also point to their role in carcinogenesis. Here, we discuss current knowledge and future directions in FFAR research related to CRC. Contradictory results of FFARs modulation may derive from the pleiotropic effects of FFAR ligands, receptor distribution and different signal transduction. Hence, we indicate directions of further studies to fully use the potential of FFARs in CRC.

Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions

2022 ◽  
Author(s):  
Muhammad Tufail ◽  
Changxin Wu
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Predictive Biomarkers ◽  
Cancer Growth ◽  
Pharmaceutical Companies ◽  
Future Directions ◽  
System Complexity ◽  
Deadly Disease ◽  
Trial Failure ◽  
Shed Light

IGF-1Rs enact a significant part in cancer growth and its progress. IGF-1R inhibitors were encouraged in the early trials, but the patients did not benefit due to the unavailability of predictive biomarkers and IGF-1R system complexity. However, the linkage between IGF-1R and cancer was reported three decades ago. This review will shed light on the IGF-1R system, targeting IGF-1R through monoclonal antibodies, reasons behind IGF-1R trial failure and future directions. This study presented that targeting IGF-1R through monoclonal antibodies is still effective in cancer treatment, and there is a need to look for future directions. Cancer patients may benefit from using mAbs that target existing and new cancer targets, evidenced by promising results. It is also essential that the academician, trial experts and pharmaceutical companies play their role in finding a treatment for this deadly disease.

scholarly journals Aggressive Colorectal Cancer in the Young

2020 ◽  
Vol 33 (05) ◽  
pp. 298-304
Author(s):  
Blake Read ◽  
Patricia Sylla
Keyword(s):  
Colorectal Cancer ◽  
Late Onset ◽  
Tumor Biology ◽  
Population Based ◽  
Average Risk ◽  
Future Directions ◽  
Screening Guidelines ◽  
Treatment And Prevention ◽  
Rising Incidence ◽  
Related Mortality

AbstractDespite the steady decline in the incidence of colorectal cancer (CRC) and cancer-related mortality in Americans of 50 years and older over the last few decades, there has been a disturbing trend of steadily rising incidence in early-onset colorectal cancer (EOCRC), defined as CRC in those younger than 50 years. With the incidence of EOCRC increasing from 4.8 per 100,000 in 1988 to 8.0 per 100,000 in 2015, and with the decreased rates in those older than 50 years largely attributed to improved screening in the older population, new screening recommendations have recently lowered the age for screening average-risk individuals from 50 to 45. EOCRC has been found to present differently from late-onset CRC, with a higher proportion of patients presenting with left-sided and rectal cancer, more aggressive histological features, and more advanced stage at the time of diagnosis. This article reviews the most recent evidence from population-based studies and institutional series, as well as the newest screening guidelines, and provides an up-to-date summary of our current understanding of EOCRC, from clinical presentation to tumor biology and prognosis, and future directions in treatment and prevention.

scholarly journals RNA-based therapeutics for colorectal cancer: Updates and future directions

2020 ◽  
Vol 152 ◽  
pp. 104550 ◽  
Author(s):  
Jingwen Liu ◽  
Bin Guo
Keyword(s):  
Colorectal Cancer ◽  
Future Directions

scholarly journals Future Directions for Monitoring Treatment Response in Colorectal Cancer

2014 ◽  
Vol 5 (1) ◽  
pp. 44-57 ◽  
Author(s):  
Avery S. Walker ◽  
Nathan P. Zwintscher ◽  
Eric K. Johnson ◽  
Justin A. Maykel ◽  
Alexander Stojadinovic ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Treatment Response ◽  
Future Directions ◽  
Monitoring Treatment ◽  
Monitoring Treatment Response

Adjuvant Therapy for Colorectal Cancer: Past Accomplishments, Future Directions

1997 ◽  
Vol 15 (5) ◽  
pp. 435-447 ◽  
Author(s):  
David J. Vaughn ◽  
Daniel G. Haller
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Therapy ◽  
Future Directions

scholarly journals Molecular therapy of colorectal cancer: Progress and future directions

2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
Wenhao Weng ◽  
Junlan Feng ◽  
Huanlong Qin ◽  
Yanlei Ma
Keyword(s):  
Colorectal Cancer ◽  
Molecular Therapy ◽  
Future Directions

Metastatic Colorectal Cancer: Current State and Future Directions

2015 ◽  
Vol 33 (16) ◽  
pp. 1809-1824 ◽  
Author(s):  
Marwan G. Fakih
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Targeted Therapies ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Cytotoxic Agents ◽  
Braf Mutations ◽  
Curative Intent ◽  
Future Directions ◽  
Unresectable Metastatic Colorectal Cancer

Substantial improvements have been made in the management of metastatic colorectal cancer over the last two decades. The overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased from approximately 1 year during the era of fluoropyrimidine monotherapy to more than 30 months with the integration of multiple cytotoxic agents and targeted therapies. More effective therapeutic combinations have increased the rate of curative-intent surgical resections, resulting in median survival in this subgroup that exceed 5 years. Here we review the landscape of systemic therapies for unresectable metastatic colorectal cancer during the current era of targeted therapies, review the effects of RAS and BRAF mutations on clinical decision making, and reflect on future directions for the treatment of metastatic colorectal cancer.

scholarly journals Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

2015 ◽  
Vol 24 (12) ◽  
pp. 1820-1828 ◽  
Author(s):  
A. Suzanne van Harten-Gerritsen ◽  
Michiel G.J. Balvers ◽  
Renger F. Witkamp ◽  
Ellen Kampman ◽  
Fränzel J.B. van Duijnhoven
Keyword(s):  
Colorectal Cancer ◽  
Vitamin D ◽  
Cancer Progression ◽  
Epidemiological Studies ◽  
Mechanistic Studies ◽  
Future Directions ◽  
Colorectal Cancer Progression
Sign in / Sign up

Export Citation Format

Share Document